Mills J L, Rhoads G G, Simpson J L, Cunningham G C, Conley M R, Lassman M R, Walden M E, Depp O R, Hoffman H J
National Institute of Child Health and Human Development, Bethesda, MD 20892.
N Engl J Med. 1989 Aug 17;321(7):430-5. doi: 10.1056/NEJM198908173210704.
Whether taking multivitamins or folate around the time of conception can reduce a woman's risk of having a child with a neural-tube defect is controversial. To investigate this question, we examined the periconceptional use of vitamin supplements by women who had a conceptus with a neural-tube defect (n = 571), women who had had a stillbirth or a conceptus with another malformation (n = 546), and women who had had a normal conceptus (n = 573). Women with conceptuses with neural-tube defects were identified either prenatally or postnatally and were matched to control mothers for gestational age. To minimize recall bias, we interviewed nearly all the women within five months of the diagnosis of a birth defect or the birth of the infant (mean, 84 days); information on vitamin use was obtained by an interviewer who was unaware of the outcome of pregnancy. The rate of periconceptional multivitamin use among the mothers of infants with neural-tube defects (15.8 percent) was not significantly different from the rate among mothers in either the abnormal or the normal control group (14.1 percent and 15.9 percent, respectively). After adjustment for potential confounding factors, the odds ratio for having an infant with a neural-tube defect among women classified as having had full supplementation with multivitamins was 0.95 as compared with the mothers of the abnormal infants (95 percent confidence interval, 0.78 to 1.14) and 1.00 as compared with the mothers of normal infants (95 percent confidence interval, 0.83 to 1.20). There were no differences among the groups in the use of folate supplements. The adjusted odds ratio for having an infant with a neural-tube defect among those receiving the recommended daily allowance of folate was 0.97 as compared with the mothers of abnormal infants (95 percent confidence interval, 0.79 to 1.18) and 0.98 as compared with the mothers of normal infants (95 percent confidence interval, 0.80 to 1.20). We conclude that the periconceptional use of multivitamins or folate-containing supplements by American women does not decrease the risk of having an infant with a neural-tube defect.
在怀孕前后服用多种维生素或叶酸是否能降低女性生育神经管缺陷患儿的风险,这一问题存在争议。为了研究这个问题,我们调查了怀有神经管缺陷胎儿的女性(n = 571)、经历过死产或怀有其他畸形胎儿的女性(n = 546)以及怀有正常胎儿的女性(n = 573)在受孕前后使用维生素补充剂的情况。怀有神经管缺陷胎儿的女性在产前或产后被确定身份,并与对照母亲按孕周进行匹配。为尽量减少回忆偏倚,我们在出生缺陷诊断或婴儿出生后的五个月内(平均84天)对几乎所有女性进行了访谈;维生素使用信息由一名不知道妊娠结果的访谈者获取。患有神经管缺陷婴儿的母亲在受孕前后服用多种维生素的比例(15.8%)与异常对照组或正常对照组母亲的比例(分别为14.1%和15.9%)无显著差异。在对潜在混杂因素进行调整后,表示完全补充多种维生素的女性生育神经管缺陷婴儿的优势比与异常婴儿的母亲相比为0.95(95%置信区间,0.78至1.14),与正常婴儿的母亲相比为1.00(95%置信区间,0.83至1.20)。各组在叶酸补充剂的使用方面没有差异。与异常婴儿的母亲相比,叶酸摄入量达到推荐每日剂量的女性生育神经管缺陷婴儿的调整后优势比为0.97(95%置信区间,0.79至1.18),与正常婴儿的母亲相比为0.98(95%置信区间,0.80至1.20)。我们得出结论,美国女性在受孕前后使用多种维生素或含叶酸补充剂并不能降低生育神经管缺陷婴儿的风险。